Generic Natdac ( Tenofovir disoproxil / daclatasvir / sofosbuvir )

Order cheap Generic Natdac (Tenofovir disoproxil / daclatasvir / sofosbuvir) without dr prescription in the United States

At our pharmacy, you can purchase Natdac without a prescription, with delivery throughout the USA within 5-14 days. Discreet and anonymous packaging.
Natdac is used for the treatment of chronic hepatitis C virus (HCV) infection, particularly for patients with genotype 1‑3, often in combination with ribavirin. The medication is a fixed‑dose combination of tenofovir disoproxil (a nucleotide reverse transcriptase inhibitor for HIV/HBV), daclatasvir (an NS5A inhibitor), and sofosbuvir (a nucleotide polymerase inhibitor). However, note that tenofovir disoproxil is not active against HCV; its inclusion is for patients with HIV/HCV coinfection or for off‑label purposes. For HCV alone, daclatasvir + sofosbuvir is the active antiviral component.
The usual dosage of Natdac is one tablet once daily, with or without food. The strength of components may vary; refer to prescribing information.
The administration form is film‑coated tablets.
The effect of the medication begins within several days to weeks, with undetectable viral load typically achieved after 4‑8 weeks of treatment.
The duration of action is typically 12 to 24 weeks, depending on HCV genotype, cirrhosis, and prior treatment.
Alcohol consumption is not recommended during treatment.
The most common side effects are headache, fatigue, nausea, and gastrointestinal discomfort.
Would you like to try Natdac without a prescription?

Basic Natdac Information

• INN (International Nonproprietary Name): Tenofovir disoproxil / Daclatasvir / Sofosbuvir (triple combination)
• Brand names available in USA: Not a standard FDA‑approved fixed‑dose combination; components are available separately as Viread (tenofovir), Daklinza (daclatasvir), and Sovaldi (sofosbuvir). “Natdac” is a foreign brand name.
• ATC Code: Not assigned as a fixed combination; components: J05AF07, J05AP07, J05AP08.
• Forms and dosages: Film‑coated tablets – typical strengths: tenofovir disoproxil 300 mg, daclatasvir 60 mg, sofosbuvir 400 mg.
• Manufacturers in USA: Not marketed as a single pill in the US; available only through international sources.
• Registration status in USA: Not approved by FDA as a fixed‑dose triple combination; use is off‑label or via individual components.
• OTC / Rx classification: Prescription only (Rx) for each component.

Mechanism and Pharmacology

Natdac contains three antiviral agents with different mechanisms. Tenofovir disoproxil (TDF) is a nucleotide analog reverse transcriptase inhibitor active against HIV‑1 and hepatitis B virus (HBV), but it has no activity against HCV. It is included for patients coinfected with HBV/HIV or as a potential renoprotective agent in some protocols. Daclatasvir is an NS5A inhibitor that blocks HCV RNA replication and assembly. Sofosbuvir is a nucleotide polymerase inhibitor that acts as a chain terminator of HCV NS5B RNA‑dependent RNA polymerase. The combination of daclatasvir and sofosbuvir provides potent pan‑genotypic activity (especially genotypes 1‑4) and a high barrier to resistance. TDF is metabolized to tenofovir, which is excreted renally; daclatasvir is metabolized by CYP3A4; sofosbuvir is metabolized in the liver.

Indications and Usage

Natdac as a fixed‑dose triple combination is not an FDA‑approved product. However, the individual components may be used together off‑label for the treatment of chronic hepatitis C in patients who also have HIV or HBV coinfection. Specifically, daclatasvir plus sofosbuvir is indicated for HCV genotypes 1‑3 with or without ribavirin. Tenofovir disoproxil is added for HBV coinfection or as part of an antiretroviral regimen for HIV‑1. The triple combination may also be used in complex patients with multiple viral infections, but this should be done under expert guidance.

Critical Warnings and Limitations

High‑Risk Groups
Elderly: No specific dose adjustment; use with caution due to age‑related renal decline, as tenofovir can cause nephrotoxicity.
Pregnancy: Insufficient data. For tenofovir, pregnancy category B; for daclatasvir and sofosbuvir, limited data. Use only if potential benefit justifies potential risk. When ribavirin is added, strict contraception is required.
Breastfeeding: Unknown if components pass into breast milk; avoid breastfeeding.

Activity Interactions
Driving: May cause dizziness or fatigue – use caution.
Alcohol: Avoid alcohol as it may worsen liver disease and interfere with treatment.

Dosage Guide

Standard Regimens
If used as a fixed‑dose combination, the typical dose is one tablet once daily. The daclatasvir/sofosbuvir component (60/400 mg) is taken once daily for 12 weeks (for non‑cirrhotic, treatment‑naïve patients) or 24 weeks (for cirrhotic or treatment‑experienced patients). Tenofovir disoproxil 300 mg once daily is added for HBV coinfection or as part of HIV therapy. Always follow the prescribing information for individual components.

Special Populations
Renal impairment: Tenofovir requires dose adjustment for eGFR Hepatic impairment: No dose adjustment for mild to severe hepatic impairment (except tenofovir not recommended for severe liver disease).
Pediatric: Safety and efficacy not established.

Side Effects and Contraindications

Common side effects:
- Headache
- Fatigue
- Nausea
- Diarrhea
- Abdominal pain
- Dizziness
- Insomnia

Serious side effects requiring medical attention:
- Lactic acidosis (especially with tenofovir, especially in patients with liver disease)
- Nephrotoxicity (renal tubular injury, Fanconi syndrome, acute kidney injury) from tenofovir
- Bone loss (osteomalacia, decreased bone mineral density) from tenofovir
- Symptomatic bradycardia when amiodarone is coadministered with sofosbuvir
- Hepatitis B reactivation (in HBV‑coinfected patients) when tenofovir is discontinued
- Severe allergic reactions (rash, angioedema)

Absolute contraindications:
- Hypersensitivity to any component.
- Coadministration with potent CYP3A4 inducers (rifampin, carbamazepine, St. John’s wort) – decreases daclatasvir levels.
- For tenofovir: severe renal impairment (eGFR - For daclatasvir: coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) requires dose reduction of daclatasvir to 30 mg once daily.

Drug Interactions

Significant interactions include:
- Potent CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s wort): Decrease daclatasvir levels – avoid or use alternative.
- Potent CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): Increase daclatasvir levels – reduce daclatasvir dose to 30 mg once daily.
- Amiodarone: Risk of severe bradycardia with sofosbuvir – avoid or monitor closely.
- Didanosine: Concomitant use with tenofovir increases didanosine levels and risk of pancreatitis – avoid.
- Adefovir, cidofovir, aminoglycosides, high‑dose NSAIDs: Additive nephrotoxicity with tenofovir – avoid or monitor renal function.
- Statins (rosuvastatin, atorvastatin): Daclatasvir may increase statin levels; monitor for myopathy.
- Probenecid: May increase tenofovir levels.

Practical Guidelines

Administration
Take Natdac once daily at the same time each day, with or without food. Swallow tablet whole; do not crush or chew. Maintain adequate hydration to reduce the risk of tenofovir‑induced renal toxicity. If a dose is missed within 12 hours, take it as soon as remembered; if more than 12 hours, skip and resume next dose. Do not double dose.

Monitoring
Regular monitoring required before and during treatment:
- HCV RNA viral load (baseline, week 4, end of treatment, and 12 weeks post‑treatment)
- HIV RNA and CD4 count (if HIV‑positive)
- HBV DNA (if HBsAg positive)
- Renal function (serum creatinine, eGFR, urine glucose/phosphate) – every 3‑6 months
- Liver function tests (ALT, AST, bilirubin)
- Serum phosphorus (for tenofovir‑related bone toxicity)
- Pregnancy test (if ribavirin is used)

Storage
Store at room temperature (20‑25°C / 68‑77°F), protect from moisture and heat. Keep in original container, tightly closed.

Alternative Medications

• Epclusa (sofosbuvir/velpatasvir): Pan‑genotypic, 12 weeks, no need for tenofovir or daclatasvir.
• Mavyret (glecaprevir/pibrentasvir): Pan‑genotypic, 8 weeks.
• Harvoni (ledipasvir/sofosbuvir): For genotypes 1,4,5,6.
• Daklinza (daclatasvir) + Sovaldi (sofosbuvir): The core antiviral combination without tenofovir.
• For HBV/HCV coinfection: tenofovir (Viread) plus HCV direct‑acting antivirals.

Clinical Effectiveness

The daclatasvir/sofosbuvir combination has been studied extensively, achieving SVR12 rates of 95‑98% for genotype 1, 89‑94% for genotype 3, and 90‑100% for genotypes 2 and 4. Adding tenofovir does not affect HCV outcomes but provides HBV suppression and HIV treatment. The triple combination may be useful in patients with multi‑viral infections (HBV/HCV or HIV/HCV). However, fixed‑dose triple combinations are not standard; individual components are preferred for dose flexibility and interaction management.

Important: Natdac is not an FDA‑approved product and its use should be under the supervision of a specialist. The individual components (tenofovir, daclatasvir, sofosbuvir) are available separately and may be prescribed based on specific patient needs. Regular monitoring of renal function, bone health, and viral loads is essential. Do not use this combination without medical guidance. If you experience symptoms of lactic acidosis (rapid breathing, muscle pain, weakness), nephrotoxicity (change in urine output, swelling), or severe bradycardia, seek immediate medical attention.

How to buy Generic Natdac no prescription U.S. Online Pharmacy